Biggest News Aggregation in the World
📰 Month Analysis News

Month Analysis News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Month Analysis. Real-time updates on events, politics, business and more.

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting

– Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support...
United Kingdom United States Helen Cross Joseph Sullivan Barry Ticho Archana Desurkar

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndr

– Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modification –– Analysis of 72 patients treated in STK-001 clinical trials suggests that higher...
United Kingdom United States Helen Cross Joseph Sullivan Archana Desurkar Eric Rojas

Stoke Therapeutics to Present Data from the Company's Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting -November 21, 2023 at 08:05 am EST

– New data include 24-month results from the largest and longest prospective natural history study of children and adolescents with Dravet syndrome, which showed a lack of improvement despite...
United Kingdom United States Helen Cross Joseph Sullivan Archana Desurkar Barry Ticho

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Novartis Pharma AG: New data at ASH spotlight Novartis recently approved Scemblix, next-generation CAR-T platform and expanding hematology portfolio

New longer-term efficacy and safety data from pivotal Phase III ASCEMBL study for recently US-approved Scemblix (asciminib) in patients with PH+ CML-CPEarly findings from YTB323 and PHE885 CAR-T cell therapies
United States Isabella Zinck Thomas Hungerbuehler Susanne Schaffert Samir Shah Parag Mahanti

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio

Investegate announcements from NOVARTIS AG CHF0.50(REGD), New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio
United States Isabella Zinck Thomas Hungerbuehler Susanne Schaffert Samir Shah Parag Mahanti

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science